IPS Cell Reprogramming
IPS Cell Reprogramming
Accelerate disease modelling and drug discovery with high-quality iPS cells.
We reprogram patient cells into high-quality iPS cells that form the foundation for disease models and research applications. From single samples to cohort collections, we deliver reliable cellular starting material for your research.
Why iPS Cell Reprogramming Matter
Induced pluripotent stem cells (iPS cells or iPSCs) are one of the most transformative tools in modern biomedical research.
Through iPS cell reprogramming, we convert adult patient cells — such as skin or blood cells — into pluripotent cells capable of developing into almost any cell type in the body.
This process provides a reliable starting point for creating patient-relevant, human-based disease models that supports early-stage drug discovery, toxicology testing, and regenerative medicine.
With these cells, you can explore personalized therapeutic approaches, reduce reliance on animal models, and investigate treatments for degenerative diseases or tissue repair.
By combining advanced reprogramming methods with rigorous quality control, we ensure that every iPS cell line we generate aligns with international standards for quality control and is ready for your research needs.
Our IPS Cell Reprogramming Services
Our iPS cell reprogramming platform give you access to versatile, patient-specific cellular starting material that helps you:
- Understand disease biology using patient-relevant cellular models
- Support early-stage drug discovery and testing
- Enable development of personalized disease models
- Explore regenerative medicine applications
- And reduce reliance on animal models
This aligns with increasing regulatory focus, including initiatives from the FDA to promote the use of alternative models in preclinical research.
Looking for a well-characterized starting point? Explore our iPS cell lines: BIONi010-C and BIONi037-A
Your Insights, powered by iPS Cells
With iPS cell reprogramming, you gain insights into:
- Cellular mechanisms driving disease (e.g., neurodegeneration, metabolic or cardiac disorders)
- Patient-specific disease phenotypes for precision medicine
- Functional responses to experimental therapeutics
Representative data
Immunocytochemistry (ICC) staining for Pluripotency marker expression
The presence of the transcription factors OCT4, SOX2, and NANOG and the surface antigens TRA-1-60, SSEA3, and SSEA4 in human induced pluripotent stem cells (hiPSCs) verifies their ability to maintain an undifferentiated pluripotent state, making them a versatile starting material for disease modeling, drug discovery, and regenerative medicine research.
Choosing Bioneer as your partner
Partnering with us means working with a dedicated project manager and a team of experienced scientists who stay closely engaged throughout your project. We combine flexible workflows with a collaborative, human-centered approach to ensure your research moves forward efficiently and with clarity.
Established expertise
Bioneer has supported the life science community since 1982, building a strong foundation in science and technology and a solid international track record in CNS research and disease modelling in general.
A human-centered way of working
We value close collaboration and long-term relationships, focusing on clear communication and trust at every stage of a project.
Relevant publications and posters
We have extensive experience in the iPSC disease modelling space, with over 100 relevant scientific publications, including collaborations with top pharma companies and leading research groups in the field.
These publications reflect our expertise and key role in contributing to research and development across the field.
Our leadership
Bjørn Holst,
Dept. Head of Cellular Engineering and Disease Models
Kenneth Thirstrup,
R&D Manager, CNS Assays
Our Workflow
- Receipt of patient-derived starting material
- Reprogramming into induced pluripotent stem cells (iPSCs)
- Colony selection and cell expansion
- Master cell bank establishment
- Extensive quality control testing
- Delivery of validated iPSC master cell bank
We maintain a structured yet flexible workflow and keep you informed at key stages throughout the project.
Reprogramming process of somatic cells to iPSCs
Other relevant services:
- Inducible expression systems
- Maintenance of cell lines
- QC processes for cell lines
FAQ: Understanding our iPS cell reprogramming
Practical Questions
What types of patient cells can I provide for reprogramming?
We typically work with fibroblasts and PBMCs, which are the preferred starting materials for reprogramming. However, other primary cell types, such as MSCs, can also be used depending on your project.
How many samples can you process at once?
We can process anything from a single sample to larger patient cohorts. Cohort-based projects are typically handled in batches to ensure consistency and quality across samples.
How long does iPS cell reprogramming take?
Reprogramming typically takes 5–6 months from the time we receive your samples to delivery of a fully quality-controlled master cell bank.
How are the cells delivered and stored?
Once the reprogrammed iPS cells have been established and quality controlled, they are stored in liquid nitrogen until delivery. Samples are typically shipped on dry ice to ensure stability during transport.
How do you perform iPS cell reprogramming?
We use advanced, non-integrating reprogramming methods, including episomal plasmids and synthetic self-replicating RNA. These approaches enable safe, efficient, and reproducible conversion of adult cells into iPS cells. We can support projects ranging from single patient samples to larger cohort collections.
How do you ensure quality and reliability?
Every iPS cell line we generate undergoes rigorous quality control in line with ISSCR guidelines. This includes confirming cell identity (STR profiling), verifying pluripotency and tri-lineage differentiation, and ensuring absence of contaminants such as Mycoplasma.
We also assess genome integrity using G-banding and ddPCR CNV analysis. Together, these steps ensure that your iPS cells are reliable and ready for disease modelling, drug discovery, and other research applications.
Can I request specific reprogramming approaches for my project?
Yes. For fibroblasts, we typically use either synthetic self-replicating RNA or non-integrating episomal plasmids, while PBMCs are reprogrammed using episomal plasmids. We are happy to align the approach with your specific project needs where possible.
What support do you provide if I need cohort collections?
We support cohort-based projects through an in-house tracking system that follows your samples from receipt of primary cells through to fully quality-controlled iPS cell lines.
As part of this process, we perform STR identity analysis on both the original patient material and the generated iPS cells, ensuring full traceability to your clinical data.
How do iPS cells differ from embryonic stem cells?
Induced pluripotent stem (iPS) cells and embryonic stem cells (ESCs) are similar in many ways, but they differ in their origin, ethical implications, and some biological properties. Whereas ESC’s are derived from the inner cell mass of a very early embryo, iPSCs are generated from adult somatic cells (such as skin or blood cells).
How can iPS cells help reduce animal testing in research?
iPS cells provide human-based models that can be used to study disease mechanisms and test new therapies in vitro. This makes it possible to reduce reliance on animal models, particularly in early-stage research, while generating data that is more directly translatable to human biology.
Contact us for a free consultation
Interested in learning how we can support your project or pipeline?
We´re always happy to chat.
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
